1[1]Nicklin JL,Copeland LJ.Endometrial papillary serous carcinoma:atterns of spread and treatment.Clin Obstet Gynecol,1996,39:686-695.
2[2]Slomovitz BM,Burke TW,Eifel PJ,et al.Uterine papillary serous carcinoma (UPSC):a single institution review of 129 cases.Gynecol Oncol,2003,91:463-469.
3[3]Chan JK,Loizzi V,Youssef M,et al.Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium.Gynecol Oncol,2003,90:181-185.
5[5]Menendez JA,Vellon L,Lupu R.Antitumoral actions of the anti-obesity drugorlistat (XenicalTM) in breast cancer cells:blockade of cell cycle progression,promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.Ann Oncol,2005,16:1253-1267.
6[6]Sebastiani V,Visca P,Botti C,et al.Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma.Gynecol Oncol,2004,92:101-105.
7[7]Rendina AR,Cheng D.Characterization of the inactivation of rat fatty acid synthase by C75:inhibition of partial reactions and protection by substrates.Biochem J,2005,388(Pt 3):895-903.
8[8]Menendez JA,Vellon L,Lupu R.Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells:blockade of cell cycle progression,promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.Ann Oncol,2005,16:1253-1267.
9[9]Menendez JA,Vellon L,Mehmi I,et al.Inhibition of fatty acid synthase (FAS) suppresses HER2_neu (erbB-2) oncogene overexpression in cancer cells.Proc Natl Acad Sci USA,2004,101:10715-10720.
10[10]Vorgias G,Strigou S,Varhalama E,et al.The effect of hypertension and anti-hypertensive drugs on endometrial thickness and pathology.Eur J Obstet Gynecol Reprod Biol,2006,125:239-242.
